Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$1,156.73 USD

1,156.73
3,056,914

-17.88 (-1.52%)

Updated Aug 31, 2026 04:04 PM ET

After-Market: $1,160.60 +3.87 (0.33%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (101 out of 248)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Harendra Ray headshot

3 Momentum Stocks That Could Continue Their Strong Run in 2026

by Harendra Ray

AI and healthcare momentum remain strong heading into 2026. NVDA, AVGO and LLY stand out as high-growth leaders with earnings power still driving their rallies.

Ahan Chakraborty headshot

Can Higher-Dose Wegovy Help Novo Nordisk Regain Obesity Market Share?

by Ahan Chakraborty

NVO seeks approval for a 7.2 mg Wegovy dose after study data showed stronger weight loss that can challenge Zepbound's U.S. momentum.

Sundeep Ganoria headshot

Pfizer Issues Soft 2026 View: What Does It Mean for the Stock's Future?

by Sundeep Ganoria

PFE's soft 2026 outlook spooks investors, with revenue and EPS guidance trailing expectations as COVID-19 demand fades and patent losses mount.

Kinjel Shah headshot

Eli Lilly or Merck: Where Should Investors Put Their Money?

by Kinjel Shah

LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer valuation.

Sundeep Ganoria headshot

How AbbVie's Pipeline Is Lining Up Key Product Launches

by Sundeep Ganoria

ABBV is lining up multiple late-stage launches, from Rinvoq label expansions to Parkinson???s and oncology assets nearing FDA decisions.

Zacks Equity Research

CHMP Backs Higher-Dose Wegovy as Novo Nordisk Seeks 2026 EU Approval

by Zacks Equity Research

NVO gains CHMP backing for a higher-dose Wegovy, paving the way for potential EU approval in 2026 as study data show stronger weight loss.

Zacks Equity Research

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Why the Market Dipped But Eli Lilly (LLY) Gained Today

by Zacks Equity Research

Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a +1.8% change compared to its last close.

Zacks Equity Research

Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win

by Zacks Equity Research

LLY's retatrutide posts strong weight-loss and pain-reduction results in its first Phase III study, boosting investor optimism.

Ahan Chakraborty headshot

NVO Down 42% Year to Date: Is This an Indication to Sell the Stock?

by Ahan Chakraborty

Novo Nordisk stock plunges 42% so far in 2025 as GLP-1 competition, price cuts, guidance trims and restructuring plans cloud growth and elevate execution risks.